RESEARCH LETTER: Pulmonary function and risk of Alzheimer dementia: two-sample Mendelian randomization study

Tom C. Russ,^{1,4*} Sarah E. Harris,⁴ G. David Batty^{1,5}

- ^{1.} Alzheimer Scotland Dementia Research Centre, University of Edinburgh;
- ^{2.} Edinburgh Dementia Prevention Group, University of Edinburgh;
- ^{3.} Division of Psychiatry, Centre for Clinical Brain Sciences, University of Edinburgh;
- ^{4.} Lothian Birth Cohorts, Department of Psychology, University of Edinburgh;
- ^{5.} UCL Research Department of Epidemiology & Public Health, University College London

* Correspondence to: Dr Tom Russ, Alzheimer Scotland Dementia Research Centre,
University of Edinburgh, 7 George Square, Edinburgh, EH8 9JZ, UK
Telephone: +44 (0)131 650 4340; Email: T.C.Russ@ed.ac.uk

Manuscript statistics: 998 words with one table

Funding: This article received no specific funding. The Alzheimer Scotland Dementia Research Centre is funded by Alzheimer Scotland. The Lothian Birth Cohorts are funded by Age UK. TCR is employed by the UK National Health Service and the Scottish Government. GDB is supported by the UK Medical Research Council (MR/P023444/1) and the US National Institute on Aging (1R56AG052519-01; 1R01AG052519-01A1). All researchers are independent of their funders.

Conflicts of interest: none

Author contributions: TCR and GDB conceived the study, SEH obtained and analysed the data, TCR drafted the manuscript and all authors revised it for intellectual content. TCR is the guarantor of the article.

1 ABSTRACT

2 Dementia is a major global public health concern and in addition to recognised risk factors
3 there is emerging evidence that poorer pulmonary function is linked with subsequent
4 dementia risk. However, it is unclear if this observed association is causal or whether it might
5 result from confounding. Therefore, we present the first two-sample Mendelian
6 randomisation study of the association between pulmonary function and Alzheimer dementia
7 using the most recent genome-wide association studies to produce instrumental variables for
8 both. We found no evidence of a causal effect of reduced Forced Expiratory Volume in 1
9 second (FEV₁) or Forced Vital Capacity (FVC) on Alzheimer dementia risk (both $P > 0.35$).
10 However, the FEV₁/FVC ratio was associated with Alzheimer dementia risk with, in fact,
11 superior function predicting an increased dementia risk (OR 1.12, 95%CI 1.02-1.23;
12 $P = 0.016$) which may result from survivor bias. While we can conclude that there is no causal
13 link between impaired pulmonary function and Alzheimer dementia, our study sheds less light
14 on potential links with other types of dementia.

15 Dementia is a major growing global public health problem.¹ Alzheimer disease risk is thought
16 to be raised in the presence of relatively few environmental and genetic factors including
17 lower educational attainment, hypertension, obesity, diabetes, cigarette smoking, and the
18 APOE $\epsilon 4$ allele.²
19
20 Recent findings also suggest that impaired pulmonary function is consistently associated with
21 ~40% elevation in later dementia risk.³ While there is mechanistic evidence to support this
22 — including hypoxia from extended sub-optimal ventilatory function⁴ — crucially, given the
23 observational nature of these studies, it is unclear if this relationship is causal. An obstacle to
24 drawing causal inference from such studies is the perennial problem of confounding — that
25 characteristics of people poorer pulmonary function differ from the unexposed in various ways
26 that may explain the association. Investigators attempt to include as many relevant covariates
27 as possible but the possibility of confounding by unmeasured/imprecisely quantified factors is
28 universal. Mendelian randomisation (MR) has been seen as a possible remedy to this problem⁵
29 and has been extended to two-sample MR where genetic associations for the exposure and
30 outcome are obtained from independent samples.⁶ Accordingly, for the first time to our
31 knowledge, we present a two-sample MR study to clarify whether the observed association
32 between poorer pulmonary function and subsequent Alzheimer dementia (AD) is causal.

33

34 METHODS

35 We ran a two-sample MR using summary data from the UKBiobank/SpiroMeta Consortium
36 Genome-Wide Association Study (GWAS) comprising 400,102 individuals.⁷ We derived two
37 genetic instruments for lung function: Forced Expiratory Volume in one second (litres; FEV₁)
38 and Forced Vital Capacity (litres; FVC). Of the 279 SNPs associated with lung function, but

not smoking, only those related to the relevant trait with $P < 5 \times 10^{-8}$ and the same direction of effect in UKBiobank and SpiroMeta were used as genetic instruments. In addition, we included a more exploratory measure: the FEV₁/FVC ratio — which has been used in the diagnosis of chronic obstructive pulmonary disease whereby lower values are more suggestive of this condition.⁸ For the outcome we used summary data from the most recent GWAS which included 21,982 people with AD and 41,944 controls.⁹ The models used the TwoSampleMR R package.¹⁰ Since this study used publicly available data, no ethical approval was required.

47

48 RESULTS

Table 1 shows the relationship between lung function and subsequent AD risk. There was no evidence of a causal effect of poorer lung function — using FEV₁ or FVC — on AD risk (both $P > 0.35$). However, each SD increase in FEV₁/FVC ratio (indicating superior lung function) was associated with an increased AD risk (OR, 95%CI 1.12, 1.02-1.23; $P = 0.016$). The MR Egger intercept for the latter indicates little horizontal pleiotropy ($\beta = 0.0002$, $P = 0.96$) and the inverse-variance weighted Q-value (177.7, $P = 0.08$) suggests no substantial heterogeneity. Using the weighted median method gave a similar result (1.15, 1.00-1.31; $P = 0.048$).

56

57 DISCUSSION

We found that the observed association between lower pulmonary function and AD risk was not supported as being causal. Thus, it is possible that the original relationship resulted from confounding by one or more unmeasured/poorly measured confounders. Multiple candidates exist including an adverse intrauterine environment leading to reduced maximal lung function, exposure to environmental factors (e.g., tobacco smoke, atmospheric pollution)

63 affecting lung function and development, and socioeconomic factors (poverty, educational
64 failure, and less-advantaged social class). In our systematic review and meta-analysis, most
65 included studies took account of smoking and cardiovascular disease risk factors, and slightly
66 fewer included height.³ Socioeconomic position was variably accounted for and there was
67 little coverage of the whole life course in terms of all included covariables.

68

69 The FEV₁/FVC ratio has not been routinely examined in relation to dementia risk.³ However,
70 we found a link — albeit a weak one — between higher pulmonary function captured by this
71 measure and increased AD risk. This may possibly be explained by survivor bias, with
72 participants with poorer pulmonary function dying before they reach late life, but a false
73 positive result must also be considered.

74

75 MR uses genetic variants which are randomly allocated at conception — and therefore
76 generally independent of confounders that may otherwise bias an association when using
77 observational methods — as proxies for environmental exposures. This assumes that genetic
78 variants are:

79 (1) associated with the exposure; (2) only associated with the outcome of interest via their
80 effect on the exposure; and 3) independent of confounders. It also relies on the exposure
81 being accurately measured in the GWAS from which the instrument is derived. Pulmonary
82 function was accurately measured with rigorous quality control in both UKBiobank (87.2%
83 participants) and the individual studies of the SpiroMeta consortium.⁷ Pathway analysis
84 suggested biological plausibility for the SNPs used as instruments with enrichment of genes
85 relating to extracellular matrix organisation and ciliogenesis.⁷ Furthermore, a genetic risk
86 score comprising all 279 lung function SNPs predicted COPD.⁷ It is unlikely that collider bias

87 due to smoking and height adjustment in the lung function GWAS explains the observed
88 association, as SNPs associated with smoking behaviour were excluded and a sensitivity
89 analysis excluding the 12 SNPs included in our instrument which were associated with height
90 in UKBiobank did not affect our conclusions.

91

92 The AD GWAS included 46 case-control studies from four consortia; rates of APOE e4
93 carriage are not reported.⁹ These studies used various methods of ascertaining dementia, with
94 multiple diagnostic criteria being applied. Some studies used clinical diagnoses and some
95 identified Alzheimer-type pathology post mortem. This variation is likely to affect the
96 applicability of the GWAS findings in our analysis.

97

98 In contrast to the instrumental AD variable used here, most observational studies use a more
99 general category of ‘dementia.’^{13,9} This lack of clarity is common and the multiple diseases
100 causing the dementia syndrome — e.g., Alzheimer disease, cerebrovascular disease, Lewy
101 body disease, and Frontotemporal Lobar Degenerative syndromes — are frequently
102 conflated. Depending on the methodology used, clarifying an individual’s precise diagnosis
103 can be challenging. For example, death certificates frequently only record the broad dementia
104 syndrome. Thus, while we can conclude that there is no causal link between impaired
105 pulmonary function and AD, our study sheds less light on potential links with other types of
106 dementia. It is plausible that there may be a different relationship between pulmonary
107 function and vascular dementia, for instance.

REFERENCES

1. Prince MJ, Wimo A, Guerchet M, Ali G-C, Wu Y-T, Prina AM. *World Alzheimer Report 2015. The Global Impact of Dementia: an analysis of prevalence, incidence, cost and trends*. London: Alzheimer's Disease International; 2015.
2. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. *The Lancet*. 2020;396(10248):413-446.
3. Russ TC, Kivimaki M, Batty GD. Respiratory Disease and Lower Pulmonary Function as Risk Factors for Dementia: A Systematic Review With Meta-analysis. *Chest*. 2020.
4. Horsburgh K, Wardlaw JM, van Agtmael T, et al. Small vessels, dementia and chronic diseases – molecular mechanisms and pathophysiology. *Clinical Science*. 2018;132(8):851-868.
5. Davey Smith G, Ebrahim S. 'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? *International Journal of Epidemiology*. 2003;32(1):1-22.
6. Hartwig FP, Davies NM, Hemani G, Davey Smith G. Two-sample Mendelian randomization: avoiding the downsides of a powerful, widely applicable but potentially fallible technique. *International Journal of Epidemiology*. 2017;45(6):1717-1726.
7. Shrine N, Guyatt AL, Erzurumluoglu AM, et al. New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. *Nature Genetics*. 2019;51(3):481-493.
8. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. *Am J Respir Crit Care Med*. 2007;176(6):532-555.
9. Kunkle BW, Grenier-Boley B, Sims R, et al. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nature Genetics*. 2019;51(3):414-430.
10. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. *PLOS Genetics*. 2017;13(11):e1007081.

Table 1. Estimates of the association between pulmonary function (FEV₁, FVC, and FEV₁/FVC ratio) and Alzheimer dementia from a two-sample Mendelian randomization

	N SNPs	F-statistic	Method	OR (95% CI)	P
FEV ₁	179	70.0	Inverse variance		
			weighted	1.06 (0.94-1.19)	0.355
FVC	133	65.1	Inverse variance		
			weighted	0.98 (0.85-1.14)	0.815
FEV ₁ /FVC ratio	154	128.3	Inverse variance		
			weighted	1.12 (1.02-1.23)	0.016
			MR Egger estimate	1.11 (0.90-1.38)	0.3188
			Weighted median	1.15 (1.00-1.31)	0.0480